BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
Remote Headphones: Improve Your Sound Insight - 2Extraordinary Shows to Long distance race on a Plane
- 3Instructions to Warmly greet Certainty and Appeal
- 4Instructions to Arrange Your Compensation During Medical caretaker Prospective employee meetings
- 5Step by step instructions to Pick A Pre-owned vehicle Stage
- Slims down for Maintainable Weight reduction
- Best Internet based Course for Learning Another Dialect: Which Stage Do You Like?
- Avoid Slam: Clearing the Street for the Eventual fate of Standard Size Trucks
- Vote In favor of Your #1 sort of film
- ‘Slender Man’ attacker back in custody. What we know about Morgan Geyser's disappearance and what happens next.
- Pick Your Top Method for starting the Morning
- 'Stranger Things' character guide: The nerds, the newcomers and the rest of the Season 5 cast
- Day to day Temporary Positions That Compensate Fairly in the US
- Baikonur launch pad damaged after Russian Soyuz launch to International Space Station
